Evidence map›Paper›PMID 39718609›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Gold nanoparticles mediate suppression of angiogenesis and breast cancer growth via MMP-9/NF-κB/mTOR and PD-L1/PD-1 signaling: integrative in vitro validation and network pharmacology insights.

Alaa Elmetwalli, Tarek El-Sewedy, Mervat G Hassan, Mohamed O Abdel-Monem, Jihan Hassan, Nadia F Ismail, Afrah Fatthi Salama, Junjiang Fu, Nasser Mousa, Deema Kamal Sabir and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alaa ElmetwalliDepartment of Clinical Trial Research Unit and Drug Discovery, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. dr.prof2011@gmail.com.ORCID 0000-0001-5372-4297
Tarek El-SewedyDepartment of Applied Medical Chemistry, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Mervat G HassanDepartment of Botany and Microbiology, Faculty of Science, Benha University, Benha, 33516, Egypt.
Mohamed O Abdel-MonemDepartment of Botany and Microbiology, Faculty of Science, Benha University, Benha, 33516, Egypt.
Jihan HassanDepartment of Applied Medical Chemistry, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Nadia F IsmailHealth Information Management Program, Biochemistry, Faculty of Health Science Technology, Borg El Arab Technological University, Alexandria, Egypt.
Afrah Fatthi SalamaBiochemistry Section, Chemistry Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt.
Junjiang FuKey Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, China.
Nasser MousaTropical Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Deema Kamal SabirDepartment of Medical Surgical Nursing, College of Nursing, Princess Nourah bint Abdulrahman University, P.O.Box 84428, 11671, Riyadh, Saudi Arabia.
Ola El-EmamClinical Pathology Department, Mansoura University, Mansoura, Egypt.
Ghada HamdyHigher Technological Institute of Applied Health Sciences, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.
Ali H El-FarKey Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gold nanoparticles (AuNPs) have emerged as promising candidates for cancer therapy due to their unique physicochemical properties and biocompatibility. In this study, we investigate the synthesis, characterization, and therapeutic potential of AuNPs in breast cancer treatment. Further, it establishes a comprehensive understanding of the mechanisms by which AuNPs suppress angiogenesis and breast cancer growth, identifying novel targets and signaling nodes contributing to the anti-tumor effects of AuNPs. AuNPs were synthesized and characterized using UV-Vis, crystallography, transmission electron microscopy (TEM), and energy-dispersive X-ray spectroscopy (EDX). The cytotoxicity of AuNPs was evaluated in WI-38 normal cells and MCF-7 breast cancer cells using the MTT assay. Additionally, the antioxidant activity of AuNPs was assessed through free radical scavenging and lipid peroxidation inhibition assays. Gene expression and pathway enrichment analyses were performed to elucidate the molecular mechanisms underlying the therapeutic effects of AuNPs in breast cancer. UV-Vis spectroscopy confirmed the successful synthesis of AuNPs, with a strong peak observed at 488.9 nm. Crystallography and TEM analysis revealed the crystalline nature and uniform size distribution of AuNPs, respectively. AuNPs exhibited concentration-dependent cytotoxic effects on MCF-7 cells, significantly inhibiting cancer cell proliferation at lower concentrations. Moreover, AuNPs demonstrated potent antioxidant activity, surpassing the effectiveness of vitamin C in scavenging free radicals and inhibiting lipid peroxidation. Gene expression analysis revealed modulation of crucial cancer-related genes and signaling pathways, including MMP-9/NF-κB/mTOR, PD-L1 expression and PD-1 checkpoint pathway, TNF signaling pathway, and adipocytokine signaling pathway, suggesting their potential as novel therapeutics for breast cancer treatment. Our findings support the promising role of AuNPs as effective and targeted therapeutics for breast cancer treatment. Further research is warranted to elucidate the precise mechanisms of action and evaluate the clinical efficacy and safety of AuNP-based therapies in breast cancer patients.

Indexed as

Antineoplastic AgentsBreast NeoplasmsGoldMetal NanoparticlesNeovascularization, PathologicAngiogenesisAntioxidantsB7-H1 AntigenCell ProliferationFemaleHumansMatrix Metalloproteinase 9MCF-7 CellsNF-kappa BProgrammed Cell Death 1 ReceptorSignal TransductionAntineoplastic AgentsAntioxidantsB7-H1 AntigenCD274 protein, humanGoldMatrix Metalloproteinase 9MMP9 protein, humanMTOR protein, humanNF-kappa BPDCD1 protein, humanProgrammed Cell Death 1 ReceptorTOR Serine-Threonine KinasesBreast cancerCancer therapyCytotoxicityGene expression analysisGold nanoparticles

Identifiers

PMID39718609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.